Clinical Trials Logo

Filter by:
NCT ID: NCT02480673 Recruiting - Clinical trials for Metabolic Syndrome X

EFFECT OF Salvia Hispanica l. (CHIA) IN THE BIOCHEMICAL METABOLIC SYNDROME COMPONENTS

Start date: June 2015
Phase: N/A
Study type: Interventional

The objective of this study is to evaluate the effect of the administration of 25 g of chia per day, for 90 days on the biochemical components of the metabolic syndrome in subjects with this condition

NCT ID: NCT02475928 Recruiting - Liver Cirrhosis Clinical Trials

Zinc Supplementation in Cirrhotic Patients

ZnDCP
Start date: April 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the effect of zinc supplementation in the treatment for dysgeusia, progression disease and quality of life in patients with liver cirrhosis.

NCT ID: NCT02464683 Recruiting - Clinical trials for Pulmonary Tuberculosis

Effect of Vitamin D as Adjunctive Therapy in Patients With Pulmonary Evolution Tuberculosis

VitaminD
Start date: April 2014
Phase: Phase 4
Study type: Interventional

Tuberculosis (TB) is the second largest infectious disease that causes death in the last 4 centuries in all the world. Observational studies found an association between vitaminD and TB, suggesting a potential therapeutic role of vitaminD supplementation in patients with active tuberculosis. The hypothesis is that the administration of vitaminD is associated with changes in the levels of cytokines in patients with tuberculosis treated with first-line drugs. The aim of this study is to evaluate the effect of vitaminD supplementation on the clinical course, the time of negative smears and cultures, and the effect on the immune response in patients with pulmonary tuberculosis (TBP).

NCT ID: NCT02459249 Recruiting - Obesity Clinical Trials

Metabolic Syndrome Diagnosis and Treatment for Adults of Low Socioeconomic Status Communities

PrEVEnTYCM
Start date: April 2015
Phase: N/A
Study type: Interventional

The objective of this study is to evaluate the effect of a healthy-habits intervention tailored to the cultural, economical and social context of the target population in cardiometabolic parameters, for a population with no access to specialized health services. The intervention was designed considering environmental and economic context like availability of food and physical activity spaces; cultural factors like social and culinary traditions; individual food preferences. It encompass a selected set of behavioral and nutritional strategies aiming to achieve control of metabolic disorders involved and to reduce the risk for diabetes. The investigators' study is a nine-month clinical intervention with randomized allocation, and parallel assignment. For the first six months, the participants in the control group will receive the treatment from the primary care service by the Health Minister as implemented by the local health center, and for the intervention group participants will receive a treatment to improve the quality of the diet and promote the practice of physical activity. Both groups will be reevaluated at third, sixth and ninth-months follow-up. The physician and the nutritionist of the study will be give the recommendations for diet and advice on exercise, mainly by suggesting moderate-intensity activity, such as brisk walks for at least 150 minutes/week.

NCT ID: NCT02451774 Recruiting - Clinical trials for Acute Lymphoblastic Leukemia

Pentoxifylline In Pediatric Acute Lymphoblastic Leukemia During Induction

PTX-II
Start date: January 2015
Phase: Phase 2/Phase 3
Study type: Interventional

Recent advances in acute lymphoblastic leukemia treatment are based on a cytotoxic drug combination. Measurement of minimal residual disease in bone marrow samples at day 14 of treatment is the most powerful early predictive indicator of further relapse, and it can be applied practically to all patients with acute lymphoblastic leukemia. Even more so, it has been observed that patients who present negative minimal residual disease in bone marrow samples at day 7 during induction have a better prognosis than those achieving this at day 14. Relapse represents the main cause of treatment failure that related in the extreme with resistance to apoptosis, defining the latter as the principal mechanism of programmed cell death; it is also related with the induction of leukemic cells to senescent arrest. Pentoxifylline is a methyl-xanthine byproduct considered an unspecific inhibitor of phosphodiesterase. It inhibits nuclear factor-kappa-beta activation by different mechanisms and stimulates apoptosis induced by different drugs; thus, it can optimize the antineoplastic effect of actual treatments in order to increase the apoptosis of leukemic cells. This effect might improve the prognosis of these patients. Evaluate the safety and effect of Pentoxifylline together with antineoplastic drugs in order to study increased apoptosis and decreased senescence during the remission induction phase in pediatric patients with newly diagnosed acute lymphoblastic leukemia. To achieve this propose, we will divide patients in two groups, who will receive pentoxifylline or placebo depending on the group, in addition to conventional treatment according to the protocol standard chemotherapy schema for pediatric patients with acute lymphoblastic leukemia at our institution during the remission induction phase. In addition, we will test whether the study group exerts an impact on reaching remission earlier as compared with the control group.

NCT ID: NCT02417896 Recruiting - Acute Renal Injury Clinical Trials

Short Term Spironolactone for Prevention of Acute Kidney Injury After Cardiac Surgery

Start date: April 2013
Phase: N/A
Study type: Interventional

Our aim is to test whether short term perioperative administration of oral spironolactone could reduce incidence of postoperative acute kidney injury (AKI) in cardiac surgical patients.

NCT ID: NCT02417883 Recruiting - Clinical trials for Chronic Kidney Disease

Furosemide Stress Test as a Predictor of Tubular Function in Chronic Kidney Disease

FST-IFTA
Start date: April 2015
Phase: Phase 3
Study type: Interventional

In kidney diseases, tubule-interstitium has become much more relevant, as formerly only the glomerulus was considered to have the main importance. Kidney's tubular atrophy and interstitital fibrosis is now recognized as long term prognostic value. We aim to evaluate the function of the kidney's tubule-interstitium through furosemide excretion after intravenous administration of this drug, and correlate the rate of excretion of furosemide with interstitial fibrosis findings in scheduled kidney biopsy for patients with chronic kidney disease.

NCT ID: NCT02407769 Recruiting - Liver Cirrhosis Clinical Trials

Late Evening Supplementation With Branched Chain Amino Acids in Liver Transplantation

Start date: February 2014
Phase: N/A
Study type: Interventional

Assess the impact in body composition and handgrip strength of the nocturne supplementation by a month with BCAA (Enterex hepatic in patients awaiting liver transplantation)

NCT ID: NCT02386800 Recruiting - Clinical trials for Acute Myeloid Leukemia

CINC424A2X01B Rollover Protocol

Start date: March 5, 2015
Phase: Phase 4
Study type: Interventional

This is a long term safety study for patients that have been treated with either ruxolitinib or a combination of ruxolitinib with panobinostat, on a Novartis or Incyte sponsored study, who have been judged by the study Investigator to benefit from ongoing treatment.

NCT ID: NCT02382900 Recruiting - Clinical trials for Human Papilloma Virus

Two-dose Schedule of Quadrivalent HPV Recombinant Vaccine in 11-year-old Boys in Mexico City

Start date: February 2015
Phase: Phase 3
Study type: Interventional

In the genital tract human papilloma virus (HPV), especially types 6 and 11 cause genital warts, the commonest viral sexually transmitted disease. The HPV 16 and 18 are the most common oncogenic "high-risk" genotypes and cause approximately 70% of all cervical cancers despite the fact that are associated with other anogenital cancers, anus, vagina, vulva and penis, and cancers of the head and neck. Current estimates are that 5.2% of all cancers are HPV associated. A large number of studies, including both adult and young females, have demonstrated that HPV vaccines are highly immunogenic and induce a long lasting protection against infection. Immunogenic vaccination results in young men and boys are equally satisfactory with the quadrivalent HPV (types 6, 11, 16, 18) vaccine recommended for men. The recommended vaccination scheme includes three shots giving the second at two months and the third at six months after the initial shot. Recently, it has been shown that the use of a two shot scheme (0 and 6 months) is equally effective among girls. The purpose of this study is to determine that the immunogenicity is non-inferior in boys using a two shot scheme compared with young women and girls.